Alexandra Sebastianelli
Overview
Explore the profile of Alexandra Sebastianelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
566
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Plante M, Mahner S, Sebastianelli A, Bessette P, Lambaudie E, Guyon F, et al.
Int J Gynecol Cancer
. 2025 Jan;
35(1):100001.
PMID: 39878257
Objective: The Laparoscopic Approach to Cervical Cancer trial demonstrated that minimally invasive radical hysterectomy was associated with worse disease-free survival and overall survival among women with early-stage cervical cancer. It...
2.
Touhami O, de Guerke L, Teo Fortin L, Foo J, Provencher D, Samouelian V, et al.
Gynecol Oncol Rep
. 2024 Oct;
56:101512.
PMID: 39386924
Objective: We assessed the global distribution and academic, administrative and research outcomes of international fellows (IFs) trained in Canadian gynecologic oncology (GO) programs. Methods: A web-based survey was sent to...
3.
Auranen A, Powell M, Sukhin V, Landrum L, Ronzino G, Buscema J, et al.
Ther Adv Med Oncol
. 2024 Sep;
16:17588359241277656.
PMID: 39346117
Background: In Part 1 of the phase III RUBY trial (NCT03981796) in patients with primary advanced or recurrent endometrial cancer (EC), dostarlimab plus carboplatin-paclitaxel (CP) significantly improved progression-free survival and...
4.
Morin L, Grenier L, Foucault N, Levesque E, Fabi F, Langlais E, et al.
Curr Oncol
. 2024 Aug;
31(8):4624-4631.
PMID: 39195328
Weekly paclitaxel (WP) is a chemotherapeutic cornerstone in the management of patients with platinum-resistant ovarian carcinoma. Multiple WP dosing regimens have been used clinically and studied individually. However, no formal...
5.
Bernard J, Mehros W, Gregoire J, Douville P, Renaud M, Sebastianelli A, et al.
J Obstet Gynaecol Can
. 2022 Jul;
44(10):1047-1053.
PMID: 35779836
Objective: Universal genetic testing has become increasingly important in the management of epithelial tubo-ovarian and peritoneal carcinoma. Worldwide, reported incidences of deleterious BRCA mutations vary between 12% and 15%. We...
6.
Jamieson A, Thompson E, Huvila J, Leung S, Lum A, Morin C, et al.
Gynecol Oncol
. 2022 May;
165(2):376-384.
PMID: 35504673
Background: The role of lymph node assessment/dissection (LND) in endometrial cancer (EC) has been debated for decades, with significant practice variation between centers. Molecular classification of EC provides prognostic information...
7.
Bernard S, McLean L, Boucher S, Hebert L, Plante M, Gregoire J, et al.
Int Urogynecol J
. 2021 Sep;
32(11):2947-2957.
PMID: 34562132
Introduction And Hypothesis: There is a high prevalence of urinary incontinence among endometrial cancer survivors. They are also known to present with pelvic floor muscle alterations. Evidence on the effects...
8.
Dallaire Nantel L, Renaud M, Gregoire J, Sebastianelli A, Plante M
Int J Gynecol Cancer
. 2021 Sep;
31(10):1335-1340.
PMID: 34518241
Objective: High-grade endometrial carcinoma limited to the endometrium or a polyp is a rare clinical entity. Currently there is no consensus on standard treatment. Thus, the goal of this study...
9.
Renaud M, Sebastianelli A, Gregoire J, Plante M
J Obstet Gynaecol Can
. 2021 Sep;
44(1):21-27.
PMID: 34474173
Objectives: To compare surgical and oncological outcomes in the treatment of endometrial cancer between laparotomy and minimally invasive surgery. The secondary objective was to determine which MIS approach was the...
10.
Lapointe J, Dorval M, Chiquette J, Joly Y, Guertin J, Laberge M, et al.
Cancers (Basel)
. 2021 Jun;
13(11).
PMID: 34072979
Medical genetic services are facing an unprecedented demand for counseling and testing for hereditary breast and ovarian cancer (HBOC) in a context of limited resources. To help resolve this issue,...